Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S4WA
|
|||
| Former ID |
DNCL003330
|
|||
| Drug Name |
ASP0113
|
|||
| Synonyms |
VCL-CB01
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Cytomegalovirus infection [ICD-11: 1D82; ICD-9: 78.5] | Phase 3 | [1] | |
| Company |
Astellas
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytomegalovirus Deoxyribonucleic acid (CMV DNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01877655) A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT). U.S. National Institutes of Health. | |||
| REF 2 | VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther. 2009 Oct;11(5):572-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.